Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OMER |
---|---|---|
09:32 ET | 1118 | 3.875 |
09:36 ET | 447 | 3.84 |
09:41 ET | 4762 | 3.8 |
09:45 ET | 500 | 3.8101 |
09:48 ET | 1000 | 3.815 |
09:50 ET | 1834 | 3.87 |
09:59 ET | 1200 | 3.86 |
10:01 ET | 12091 | 3.83 |
10:03 ET | 900 | 3.84 |
10:14 ET | 11815 | 3.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Omeros Corp | 225.4M | -1.3x | --- |
Tenaya Therapeutics Inc | 224.2M | -1.7x | --- |
ATAI Life Sciences NV | 226.0M | -5.6x | --- |
Solid Biosciences Inc | 222.6M | -1.4x | --- |
Gossamer Bio Inc | 228.5M | -0.9x | --- |
Skye Bioscience Inc | 221.2M | -1.7x | --- |
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $225.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-2.90 |
Book Value | $-0.41 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.